Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities

16 Nov 2022

Abstract excerpt

Programmed cell death protein 1(PD-1) is a type of immune-inhibitory checkpoint protein, which delivers inhibitory signals to cytotoxic T cells by binding to the programmed death ligand-1 (PD-L1) displayed on the surface of cancer cells. Antibodies blocking PD-1/PD-L1 interaction have been extensively used in treatment of human malignancies and have achieved promising outcomes in recent years. However, gradual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36384676
DOI: 10.1186/s40164-022-00356-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunitiesPMID 36384676Read ↗

Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)Semantic proximity Read ↗

Epigenetic modulation in cancer immunotherapySemantic proximity Read ↗

Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applicationsSemantic proximity Read ↗

Epigenetic Mechanisms of Resistance to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Regulatory mechanisms of PD-1/PD-L1 in cancersSemantic proximity Read ↗

Epigenetic and Genetic Regulation of PDCD1 Gene in Cancer Immunology.Semantic proximity Read ↗

Epigenome-Driven Strategies for Personalized Cancer ImmunotherapySemantic proximity Read ↗

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Semantic proximity Read ↗

PD-L1: expression regulationSemantic proximity Read ↗

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune EvasionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.